Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Basiliximab

Brand: Simulect®
NICE TA: 482
Indication: Immunosuppresive therapy for kidney transplant in children and young people (NICE TA482)
Disease category: Immune system and Malignant Disease
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

NICE TA 482 guidance makes recommendations on using basiliximab, rabbit anti-human thymocyte immunoglobulin, tacrolimus (immediate-release and prolonged-release), mycophenolate mofetil, mycophenolate sodium, sirolimus, everolimus and belatacept after kidney transplant in children and young people. The recommendations apply only to the initial immunosuppressive therapy (induction and maintenance therapy) started around the time of kidney transplant.

Basiliximab, when used as part of an immunosuppressive regimen that includes a calcineurin inhibitor, is recommended as an initial option to prevent organ rejection in children and young people having a kidney transplant.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA482 - Immunosuppressive therapy for kidney transplant in children and young people

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red